Sponsor

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Clinical research sponsor

Published trials12
Recruiting shown1
Roles2
SourceClinicalTrials.gov

Clinical trials

12 shown
DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · lead sponsor · 2023-10-24
RECRUITING
The Confirmatory Olmesartan Plaque Regression StudyNCT01132768 · lead sponsor · 2010-05-01
TERMINATED
Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood PressureNCT01101009 · lead sponsor · 2010-04-01
COMPLETED
Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic SyndromeNCT00891267 · lead sponsor · 2008-10-01
COMPLETED
Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial ProtectionNCT00676845 · lead sponsor · 2008-08-01
COMPLETED
Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24NCT00679484 · lead sponsor · 2008-06-01
TERMINATED
Isolated Systolic Hypertension in the Elderly and Very ElderlyNCT00751829 · lead sponsor · 2003-07-01
COMPLETED
Olmesartan Medoxomil Versus Losartan in Elderly and Very ElderlyNCT00751751 · lead sponsor · 2003-06-01
COMPLETED
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers AnalysisNCT04132960 · collaborator · 2019-10-21
COMPLETED
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential HypertensionNCT00441350 · collaborator · 2007-07-01
COMPLETED
Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionNCT00430950 · collaborator · 2007-02-01
COMPLETED
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionNCT00430508 · collaborator · 2007-02-01
COMPLETED

Sponsor roles

lead sponsor8
collaborator4

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.